Effect of early Alzheimer's disease plasma markers on Aβ deposition: Evidence from SILCODE

Abstract Background Previous studies have found that AD‐related plasma markers are associated with Aβ deposition, but the specific effects remain unclear. Method Data were obtained from the Longitudinal Study of Cognitive Decline in China (SILCODE). Comprehensive neuropsychological assessments, MRI, plasma samples, and amyloid positron‐emission tomography (Aβ‐PET) data were collected. Through the SUVR value calculation and Aβ stage classification, as well as the correlation analysis between plasma biomarkers and voxel /ROI SUVR values and clinical scale information, respectively, mediation analysis was used to study the possible pathways. Result This study involved 148 participants from Xuanwu Hospital in Beijing, including 66 cognitively normal (CN), 59 subjective cognitive decline (SCD), 12 MCI and 11 AD patients in this dataset. The proportion of CN and SCD in stage A0‐1 was the highest, while A2‐4 MCI and AD increased. Analysis of variance showed that except Aβ42/Aβ40, the other three (p‐tau181, GFAP and NfL) plasma biomarkers had differences between groups, and GFAP showed significant differences in each stage. Plasma p‐tau181 was significantly lower in stage A0 and A1 than in stage A2 and A3. Plasma GFAP at stage A0 was significantly lower than that at stages A1, A2, and A3, and at stage 1, it was significantly lower than that at stages A2 and A3. Plasma GFAP at stage A3 was significantly higher than that at stage A4. There were two pathways that showed significant fully mediated effects: in the PET SUVR‐ plasma p‐tau181‐MMSE score pathway, all four meta‐ROI SUVR showed fully mediated effects, while in the PET SUVR‐ plasma GFAP‐MMSE score pathway, with only 2 meta‐ROI SUVR values, stage A2 and stage A4 showed mediation effects. Conclusion The present study demonstrated the role of plasma in the early stage of AD, especially SCD, from the clinical diagnosis and Aβ stage dimensions. Studies have found that P‐tau181 has a good hint role throughout the course of AD, while GFAP may have a ceiling effect in the middle stage of AD and a significant hint role in the early and late stages of AD.

Authors

Institutions

Publication Details

Journal
Alzheimer s & Dementia
Published
2024-12-01
DOI
https://doi.org/10.1002/alz.086351
Citations
1
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
0.33
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effect of early Alzheimer's disease plasma markers on Aβ deposition: Evidence from SILCODE

Jiehui Jiang, Xianfeng Yu, Ying Han, Xia Zhou et al.
1 citations
Alzheimer s & Dementia
Alzheimer's disease research and treatments
0.33
article

Effect of early Alzheimer's disease plasma markers on Aβ deposition: Evidence from SILCODE

Jiehui Jiang, Xianfeng Yu, Ying Han, Xia Zhou, Rong Shi
article en
1 citations

Abstract

Abstract Background Previous studies have found that AD‐related plasma markers are associated with Aβ deposition, but the specific effects remain unclear. Method Data were obtained from the Longitudinal Study of Cognitive Decline in China (SILCODE). Comprehensive neuropsychological assessments, MRI, plasma samples, and amyloid positron‐emission tomography (Aβ‐PET) data were collected. Through the SUVR value calculation and Aβ stage classification, as well as the correlation analysis between plasma biomarkers and voxel /ROI SUVR values and clinical scale information, respectively, mediation analysis was used to study the possible pathways. Result This study involved 148 participants from Xuanwu Hospital in Beijing, including 66 cognitively normal (CN), 59 subjective cognitive decline (SCD), 12 MCI and 11 AD patients in this dataset. The proportion of CN and SCD in stage A0‐1 was the highest, while A2‐4 MCI and AD increased. Analysis of variance showed that except Aβ42/Aβ40, the other three (p‐tau181, GFAP and NfL) plasma biomarkers had differences between groups, and GFAP showed significant differences in each stage. Plasma p‐tau181 was significantly lower in stage A0 and A1 than in stage A2 and A3. Plasma GFAP at stage A0 was significantly lower than that at stages A1, A2, and A3, and at stage 1, it was significantly lower than that at stages A2 and A3. Plasma GFAP at stage A3 was significantly higher than that at stage A4. There were two pathways that showed significant fully mediated effects: in the PET SUVR‐ plasma p‐tau181‐MMSE score pathway, all four meta‐ROI SUVR showed fully mediated effects, while in the PET SUVR‐ plasma GFAP‐MMSE score pathway, with only 2 meta‐ROI SUVR values, stage A2 and stage A4 showed mediation effects. Conclusion The present study demonstrated the role of plasma in the early stage of AD, especially SCD, from the clinical diagnosis and Aβ stage dimensions. Studies have found that P‐tau181 has a good hint role throughout the course of AD, while GFAP may have a ceiling effect in the middle stage of AD and a significant hint role in the early and late stages of AD.

Alzheimer s & DementiaVol. 20(S2)
Shanghai University (CN), Capital Medical University (CN), Anhui Medical University (CN), First Affiliated Hospital of Anhui Medical University (CN)
Good health and well-being
Openalex Percentile: Top 34%
Alzheimer's disease research and treatments
0.33
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.